Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

BENZYLPENICILLIN FOR SYSTEM SUITABILITY CRS (10 MG)

BENZYLPENICILLIN FOR SYSTEM SUITABILITY CRS (10 MG)

NA

DISCOVER
NETILMICIN FOR PEAK IDENTIFICATION CRS (15 MG)

NETILMICIN FOR PEAK IDENTIFICATION CRS (15 MG)

56391-57-2

DISCOVER
SILDENAFIL FOR PEAK IDENTIFICATION CRS (15 MG)

SILDENAFIL FOR PEAK IDENTIFICATION CRS (15 MG)

171599-83-0

DISCOVER
REMIFENTANIL HYDROCHLORIDE CRS - * NARC (100 MG)

REMIFENTANIL HYDROCHLORIDE CRS - * NARC (100 MG)

132539-07-2

DISCOVER
MILBEMYCIN OXIME CRS (110 MG)

MILBEMYCIN OXIME CRS (110 MG)

129496-10-2

DISCOVER
NETILMICIN SULFATE FOR LC ASSAY CRS (25 MG)

NETILMICIN SULFATE FOR LC ASSAY CRS (25 MG)

56391-57-2

DISCOVER
TERIPARATIDE FOR SYSTEM SUITABILITY CRS (1.3 MG)

TERIPARATIDE FOR SYSTEM SUITABILITY CRS (1.3 MG)

52232-67-4

DISCOVER
OXYTETRACYCLINE CRS (100 MG)

OXYTETRACYCLINE CRS (100 MG)

79-57-2

DISCOVER
TERLIPRESSIN CRS (1 MG)

TERLIPRESSIN CRS (1 MG)

14636-12-5

DISCOVER
TERLIPRESSIN FOR NMR IDENTIFICATION CRS (2.9 MG)

TERLIPRESSIN FOR NMR IDENTIFICATION CRS (2.9 MG)

14636-12-5

DISCOVER
TERLIPRESSIN IMPURITY MIXTURECRS (0.03 MG)

TERLIPRESSIN IMPURITY MIXTURECRS (0.03 MG)

NA

DISCOVER
DICYCLOVERINE IMPURITY A CRS (20 MG)

DICYCLOVERINE IMPURITY A CRS (20 MG)

60263-54-9

DISCOVER